ABCG2 p.Arg465Ala
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 20203106
[PubMed]
Cai X et al: "Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport."
No.
Sentence
Comment
3
K452A, K453D, H457A, R465A, and K473A were stably expressed in human embryonic kidney (HEK) cells, and their plasma membrane expression and transport activities were examined.
X
ABCG2 p.Arg465Ala 20203106:3:21
status: VERIFIED5 After normalization to BCRP levels, the activities of K452A and H457A in effluxing mitoxantrone, boron-dipyrromethene-prazosin, and Hoechst33342 were increased approximately 2to 6-fold compared with those of wild-type BCRP, whereas the activities of K453D and R465A were decreased by 40 to 60%.
X
ABCG2 p.Arg465Ala 20203106:5:260
status: VERIFIED6 Likewise, K452A and H457A conferred increased resistance to mitoxantrone and 7-ethyl-10-hydroxy-camptothecin (SN-38), and K453D and R465A exhibited lower resistance.
X
ABCG2 p.Arg465Ala 20203106:6:132
status: VERIFIED8 These mutations also differentially affected BCRP ATPase activities with a 2to 4-fold increase in Vmax/Km for K452A and H457A and a 40 to 70% decrease for K453D and R465A.
X
ABCG2 p.Arg465Ala 20203106:8:165
status: VERIFIED76 The polymerase chain reaction-based mutagenesis was performed according to the manufacturer`s instructions with the following forward primers: K452A (5Ј-gaa ctc ttt gtg gta gag GCg aag ctc ttc ata cat gaa-3Ј), K453D (5Ј-ctc ttt gtg gta gag aag GaC ctc ttc ata cat gaa tac-3Ј), H457A (5Ј-gag aag aag ctc ttc ata GCt gaa tac atc agc gga tac-3Ј), R465A (5Ј-tac atc agc gga tac tac GCa gtg tca tct tat ttc ctt-3Ј), and K473A (5Ј-tca tct tat ttc ctt gga GCa ctg tta tct gat tta tta-3Ј).
X
ABCG2 p.Arg465Ala 20203106:76:380
status: VERIFIED183 The expression levels of the mutants K452A, K453D, H457A, R465A, and K473A, determined by immunoblotting of whole-cell lysates using beta-actin as an internal standard, were approximately 0.74-, 2.56-, 0.24-, 3.87-, and 1.56-fold that of wild-type BCRP (Fig. 2, A and B).
X
ABCG2 p.Arg465Ala 20203106:183:58
status: VERIFIED191 A, a representative immunoblot of whole-cell lysates for wild-type BCRP and the mutants K452A, K453D, H457A, R465A, and K473A.
X
ABCG2 p.Arg465Ala 20203106:191:109
status: VERIFIED207 After normalization to the BCRP levels of whole-cell lysates, statistically significant differences in efflux activities for all three substrates were noticed for K452A, K453D, H457A, and R465A compared with wild-type protein.
X
ABCG2 p.Arg465Ala 20203106:207:188
status: VERIFIED209 Thus, the efflux activities of K452A and H457A were significantly increased 2to 6-fold, whereas the activities of K453D and R465A were decreased by 40 to 60%, depending on substrate (Table 1).
X
ABCG2 p.Arg465Ala 20203106:209:124
status: VERIFIED220 After normalization to the BCRP levels, the IC50 values of cells expressing K452A, K453D, H457A, and R465A for MX and SN-38 were significantly different from those of cells expressing wild-type BCRP, whereas the IC50 values of cells expressing K473A and wild-type protein were comparable.
X
ABCG2 p.Arg465Ala 20203106:220:101
status: VERIFIED221 Thus, the relative levels of resistance of K452A and H457A to MX were increased approximately 2to 3-fold compared with wild-type protein, whereas those of K453D and R465A to MX were decreased by 30 to 70%.
X
ABCG2 p.Arg465Ala 20203106:221:165
status: VERIFIED222 Likewise, the relative levels of resistance of H457A to SN-38 were increased approximately 3-fold, whereas those of K453D and R465A to SN-38 were decreased by 50 to 60%.
X
ABCG2 p.Arg465Ala 20203106:222:126
status: VERIFIED232 The Km values of K453D, R465A, and K473A were comparable with that of wild-type protein; however, the Km values of K452A and H457A were decreased by approximately 50 and 70%, respectively, suggesting that these two mutations, particularly the one at position 457, increased the binding affinity of ATP to BCRP.
X
ABCG2 p.Arg465Ala 20203106:232:24
status: VERIFIED234 After normalization to the BCRP levels, the Vmax values of K453D and R465A were approximately 60% lower than that of wild-type BCRP, whereas the Vmax values of other mutants did not change.
X
ABCG2 p.Arg465Ala 20203106:234:69
status: VERIFIED235 As a result, the Vmax/Km values of K452A and H457A were increased approximately 210 µm 10 µm 10 µm Wild-type BCRP K452A K453D 10 µm 10 µm10 µm 10 µm H457A R465A K473A Fig. 3.
X
ABCG2 p.Arg465Ala 20203106:235:190
status: VERIFIED241 Selected areas of HEK cells expressing wild-type BCRP and the mutants K452A, K453D, H457A, R465A, and K473A are shown.
X
ABCG2 p.Arg465Ala 20203106:241:91
status: VERIFIED244 In contrast, the Vmax/Km values of K453D and R465A were decreased by approximately 40 to 70%.
X
ABCG2 p.Arg465Ala 20203106:244:45
status: VERIFIED263 Mitoxantrone BODIPY-Prazosin Hoechst33342 ⌬F ⌬FЈ Ratio ⌬F ⌬FЈ Ratio ⌬F ⌬FЈ Ratio pcDNA vector 0 0 0 0 0 0 Wild-type BCRP 11.1 Ϯ 1.5 11.1 Ϯ 1.5 1.0 49.9 Ϯ 13.1 49.9 Ϯ 13.1 1.0 976.5 Ϯ 115.5 976.5 Ϯ 115.5 1.0 K452A 22.0 Ϯ 5.9 29.7 Ϯ 7.9* 2.7 76.6 Ϯ 22.5 103.5 Ϯ 30.4* 2.1 1138.3 Ϯ 134.7 1538.3 Ϯ 182.1* 1.6 K453D 19.1 Ϯ 5.9 7.5 Ϯ 3.3* 0.7 57.7 Ϯ 15.6 22.6 Ϯ 6.1* 0.4 1116.9 Ϯ 132.2 436.3 Ϯ 51.6* 0.4 H457A 4.5 Ϯ 2.1 18.7 Ϯ 8.7* 1.7 40.1 Ϯ 9.7 167.0 Ϯ 40.2* 3.3 1259.5 Ϯ 343.2 5247.9 Ϯ 1429.9* 5.4 R465A 26.1 Ϯ 3.0 6.8 Ϯ 0.8* 0.6 96.5 Ϯ 16.0 24.9 Ϯ 4.1* 0.5 2217.8 Ϯ 255.2 573.1 Ϯ 65.9* 0.6 K473A 22.2 Ϯ 5.0 14.3 Ϯ 3.2 1.3 83.2 Ϯ 17.6 53.3 Ϯ 11.3 1.1 1411.5 Ϯ 166.8 887.7 Ϯ 104.9 0.9 no effect on phycoerythrin fluorescence.
X
ABCG2 p.Arg465Ala 20203106:263:699
status: VERIFIED264 However, the addition of prazosin differentially increased the binding of 5D3 to wild-type BCRP, K452A, K453D, H457A, and R465A in a concentration-dependent manner (Fig. 6), suggesting that the binding equilibrium between prazosin and BCRP could be monitored by measuring the binding of 5D3 to the transporter.
X
ABCG2 p.Arg465Ala 20203106:264:122
status: VERIFIED265 Thus, the apparent dissociation constants of the prazosin complex with wild-type or mutant BCRP were estimated to be 5.3 Ϯ 1.1, 14.7 Ϯ 2.3, 3.1 Ϯ 0.4, 20.1 Ϯ 4.0, and 6.7 Ϯ 1.8 M for wild-type BCRP, K452A, K453D, H457A, and R465A, respectively.
X
ABCG2 p.Arg465Ala 20203106:265:262
status: VERIFIED289 Vanadate-sensitive ATPase activities of wild-type and mutant BCRP were measured with plasma membrane preparations over an ATP concentration range of 0 to 5 mM as described. Shown are means Ϯ S.D. of three independent experiments for wild-type BCRP (f), K452A (), K453D (F), H457A (‚), R465A (ࡗ), and K473A (छ).
X
ABCG2 p.Arg465Ala 20203106:289:304
status: VERIFIED297 MX SN-38 Dox Rho123 IC50 Relative Resistance (Ratio) IC50 Relative Resistance (Ratio) IC50 Relative Resistance IC50 Relative Resistance nM nM nM M pcDNA vector 24.0 Ϯ 3.5 2.4 Ϯ 0.3 24.0 Ϯ 8.7 7.26 Ϯ 1.15 Wild-type BCRP 145.1 Ϯ 52.8 6.0 (1.0) 125.3 Ϯ 6.1 52.2 (1.0) 31.5 Ϯ 12.6 1.3 10.97 Ϯ 1.84 1.5 K452A 354.8 Ϯ 68.6 14.8 (3.3)* 103.0 Ϯ 12.5 42.9 (1.1)* 24.2 Ϯ 4.4 1.0 9.27 Ϯ 1.75 1.3 K453D 244.0 Ϯ 99.9 10.2 (0.7)* 136.2 Ϯ 9.9 56.8 (0.4)* 34.0 Ϯ 6.7 1.4 8.22 Ϯ 0.97 1.1 H457A 71.9 Ϯ 12.8 3.0 (2.1)* 90.6 Ϯ 4.6 37.8 (3.0)* 21.8 Ϯ 16.6 0.9 7.61 Ϯ 1.29 1.0 R465A 169.1 Ϯ 49.0 7.0 (0.3)* 224.2 Ϯ 39.7 93.4 (0.5)* 37.9 Ϯ 17.5 1.6 14.65 Ϯ 1.26 2.0 K473A 243.1 Ϯ 114.0 10.1 (1.1) 188.0 Ϯ 19.2 78.3 (0.9) 36.0 Ϯ 10.1 1.5 15.11 Ϯ 1.43 2.1 not Lys452 , Lys453 , and Lys473 , seem to directly participate in the binding of all four substrates.
X
ABCG2 p.Arg465Ala 20203106:297:683
status: VERIFIED317 Wild-type BCRP K452A K453D H457A R465A K473A Vmax (nmol Pi/min/mg protein) 18.4 Ϯ 1.8 16.4 Ϯ 1.9 15.1 Ϯ 1.4 3.94 Ϯ 0.07 15.8 Ϯ 2.6 17.1 Ϯ 1.3 Vmax normalized to BCRP level (nmol Pi/min/mg protein) 18.4 Ϯ 1.8 18.4 Ϯ 2.1 7.4 Ϯ 0.7 19.6 Ϯ 0.3 6.7 Ϯ 1.1 17.6 Ϯ 1.3 Km for ATP (mM) 0.69 Ϯ 0.21 0.32 Ϯ 0.15 0.85 Ϯ 0.12 0.17 Ϯ 0.07 0.46 Ϯ 0.11 0.52 Ϯ 0.13 Vmax/Km (nmol Pi/min/mg protein/mM) 26.7 57.5 8.7 115.3 14.6 33.8 0 25 50 75 100 -0.25 0.00 0.25 0.50 0.75 1.00 1.25 Prazosin (µM) ∆F/F0 Fig. 6.
X
ABCG2 p.Arg465Ala 20203106:317:33
status: VERIFIED319 The concentration-dependent effects of prazosin on the binding of 5D3 to wild-type and mutant BCRP over a concentration range of 0 to 100 M were determined by using flow cytometry as described. Shown are means Ϯ S.D. of three independent experiments for the pcDNA control (f), wild-type BCRP (Œ), K452A (छ), K453D (ࡗ), H457A (F), R465A (Ⅺ), and K473A (‚).
X
ABCG2 p.Arg465Ala 20203106:319:362
status: VERIFIED329 In contrast, substitutions of Lys453 and Arg465 with Asp (K453D) or Ala (R465A) caused a nonselective global reduction in BCRP activity (Tables 1 and 2).
X
ABCG2 p.Arg465Ala 20203106:329:73
status: VERIFIED363 K452A and H457A were associated with a 50 to 70% decrease in Km and a 2to 5-fold increase in Vmax/Km for ATP hydrolysis, whereas the Vmax/Km values of K453D and R465A were decreased by 40 to 70%, and the Km values of K453D and R465A did not change much (Table 3).
X
ABCG2 p.Arg465Ala 20203106:363:161
status: VERIFIEDX
ABCG2 p.Arg465Ala 20203106:363:162
status: NEW364 This suggests that ATP binding affinity and/or the efficiency of ATP hydrolysis are increased for K452A and H457A, but decreased for K453D and R465A, thus affecting BCRP activity accordingly.
X
ABCG2 p.Arg465Ala 20203106:364:143
status: VERIFIED375 Prazosin differentially increased 5D3 binding to wild-type BCRP, K452A, K453D, H457A, and R465A, but had little effect on 5D3 binding to K473A (Fig. 6).
X
ABCG2 p.Arg465Ala 20203106:375:90
status: VERIFIED
PMID: 25036722
[PubMed]
Szafraniec MJ et al: "Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2)."
No.
Sentence
Comment
209
Position Type of mutation Effect on the transporter References NBD Lys 86 Met (i) No stimulation of the ATPase activity by prazosin; (ii) no influence on the transport of mitoxantrone Henriksen et al. (2005b) Glu 126 stop, Phe 208 Ser, Ser 248 Phe, Glu 334 stop Inability to transport hematoporphyrin Tamura et al. (2006) Glu 211 Gln Complete abolishment of the ATPase activity and methotrexate transport Hou et al. (2009) Pro 392 Ala Significant reduction in the efflux activity of mitoxantrone, BODIPY-prazosin and Hoechst 33342 Ni et al. (2011) TM1 Gly 406 Ala Gly 410 Ala No influence on the activity of the transporter Polgar et al. (2004) Gly 406 Leu Gly 410 Leu (i) Loss of the ability to transport rhodamine123; (ii) impaired transport of mitoxantrone, Pheide and BODIPY-prazosin Polgar et al. (2004) Extracellular loop 1 Phe 431 Leu (i) Loss of the ability to transport methotrexate; (ii) 10% level of hematoporphyrin transport compared to the WT protein Tamura et al. (2006) Ser 441 Asn Inability to transport hematoporphyrin Tamura et al. (2006) Ser 441 Asn Loss of the ability to transport methotrexate Tamura et al. (2006) TM2 Lys 452 Ala His 457 Ala Increase in transport of mitoxantrone, BODIPY-prazosin and Hoechst 33342 Cai et al. (2010) Lys 453 Ala Arg 465 Ala Decrease in transport of mitoxantrone, BODIPY-prazosin, Hoechst 33342, doxorubicin, SN-38 and rhodamine 123 Cai et al. (2010) TM3 Arg 482 Gly Arg 482 Thr (i) No change in the inhibitory activity of lapatinib; (ii) about two times greater inhibition by ritonavir, saquinavir and nalfinavir than in the WT variant; (iii) gaining the ability to transport rhodamine123 and doxorubicin; (iv) no influence on the transport of mitoxantrone; (v) loss of the ability to transport methotrexate Dai et al. (2008), Gupta et al. (2004), Honjo et al. (2001), Mitomo et al. (2003) Arg 482 Thr (i) Lower IC 50 of cyclosporine A for mutant than for WT variant; (ii) lower elacridar inhibition potency Xia et al. (2007) Arg 482 Lys Complete loss of transport activity Ejendal et al. (2006) Phe 489 Leu Impaired transport of porphyrins, no transport of methotrexate Tamura et al. (2006) Extracellular loop 3 Asn 590 Tyr Over twice reduced transport of mitoxantrone, topotecan, daunorubicin and rhodamine 123 Vethanayagam et al. (2005) Cys 592 Ala/Cys 608 Ala (i) Transport of mitoxantrone almost unchanged; (ii) transport of BODIPY-prazosin significantly impaired Henriksen et al. (2005a) Extracellular loop 3 Cys 603 Ser Cys 592 Ser/Cys 608 Ser Cys 592 Ser/Cys 603 Ser/Cys 608 Ser Diminished susceptibility to the inhibitory activity of fumitremorgin C Shigeta et al. (2010) Cys-less Arg 482 Gly-BCRP Complete loss of the ability to efflux mitoxantrone Liu et al. (2008b) The positions of the amino acid residues refer to the topological model of BCRP proposed by Wang et al. (2009).
X
ABCG2 p.Arg465Ala 25036722:209:1267
status: NEW